TY - JOUR
T1 - Clinical use of erythropoietin.
AU - Henry, D. H.
AU - Spivak, J. L.
PY - 1995/3
Y1 - 1995/3
N2 - Recombinant human erythropoietin has been available for clinical use since 1985. It was an immediate success in treating the anemia of chronic renal failure and has also enjoyed some objective success in the treatment of other anemias in either a therapeutic or prophylactic setting, but the issues of appropriate patient selection and cost-benefit ratios are still unresolved. This review discusses the most recent literature concerning the use of recombinant human erythropoietin for the anemia associated with cancer, HIV infection, myelodysplasia, prematurity, autologous blood transfusion, bone marrow transplantation, and chronic renal failure.
AB - Recombinant human erythropoietin has been available for clinical use since 1985. It was an immediate success in treating the anemia of chronic renal failure and has also enjoyed some objective success in the treatment of other anemias in either a therapeutic or prophylactic setting, but the issues of appropriate patient selection and cost-benefit ratios are still unresolved. This review discusses the most recent literature concerning the use of recombinant human erythropoietin for the anemia associated with cancer, HIV infection, myelodysplasia, prematurity, autologous blood transfusion, bone marrow transplantation, and chronic renal failure.
UR - http://www.scopus.com/inward/record.url?scp=0029257781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029257781&partnerID=8YFLogxK
U2 - 10.1097/00062752-199502020-00003
DO - 10.1097/00062752-199502020-00003
M3 - Review article
C2 - 9371981
AN - SCOPUS:0029257781
SN - 1065-6251
VL - 2
SP - 118
EP - 124
JO - Current opinion in hematology
JF - Current opinion in hematology
IS - 2
ER -